

L3: Entry 14 of 33

File: USPT

Jul 6, 1999

DOCUMENT-IDENTIFIER: US 5919754 A

TITLE: Method of inhibiting fibrinogen binding to endothelial cells with


fibrinogen gamma chain peptides

DEPR:

The phenotypical changes in cell surface adhesion receptors during monocytic differentiation of HL-60 cells were quantitated by flow cytometry as described in Languino, et al supra and Example 7C. The monoclonal antibodies used in the assay included the following: BK (also known as LB-2; Becton Dickinson) which recognizes ICAM-1, IB4 which recognizes the .beta..sub.2 integrin subunit CD18 (Wright et al., Proc. Natl. Acad. Sci. U.S.A., 85:7734-7738 (1988)), LM609 which recognizes .alpha..sub.v .beta..sub.3, OKM1 which recognizes CD.sup.11 b (Cheresh, Proc. Natl. Acad. Sci. U.S.A., 84:6471-6475 (1987), and 142 which recognizes .alpha..sub.v (D. A. Cheresh, The Scripps Research Institute, San Diego, Calif.).

DEPR:

Results indicated minimal changes in the surface density of the B.sub.2 integrin subunit CD18 detected by IB4 and .alpha..sub.v detected by 142, an approximate 15-20 fold increase of the .alpha. subunit.(.alpha..sub.M, CD11b) of the leukocyte fibrinogen receptor CD11b/CD18 detected by OKM1, a 6-20 fold increase in .alpha..sub.v .beta..sub.3 integrin as detected by $\underline{\text{LM609}}$ but with considerable heterogeneity, and an approximate 10 fold increase in ICAM-1 as detected by BD.



Search Results -

Term _	Documents	
ALPHAVBETA3.USPT.	1	
ALPHAVBETA3S	$\overline{0}$	
ALPHAV.USPT.	4	
ALPHAVS .	0	
BETA3.USPT.	39	
BETA3S	0	
(ALPHAVBETA3 OR (ALPHAV ADJ BETA3)).USPT.		

US Patents Full-Text Database	Ŀ
US Pre-Grant Publication Full-Text Database	Τ
JPO Abstracts Database	
EPO Abstracts Database	
Derwent World Patents Index	
IBM Technical Disclosure Bulletins	t
	Ľ


Database:

	alphavbeta3	or alpha	7 adj k	beta3	•	
Refine Search:					₹	Clear

Search History


Today's Date: 4/2/2001

DB Name	<u>Query</u>	Hit Count	Set Name
USPT	alphavbeta3 or alphaV adj beta3	1	<u>L4</u>
USPT	lm609	33	<u>L3</u>
USPT	cheresh-david\$	3	<u>L2</u>
USPT	brooks-peter\$	34	<u>L1</u>



Search Results -

Term	Documents
LM609.DWPI,EPAB,JPAB.	4
LM609S	0
LM609.JPAB,EPAB,DWPI.	4




	lm609	\exists	
Refine Search:	·	₹	Clear
			·

Search History


Today's Date: 4/2/2001

DB Name	Query	Hit Count	Set Name
JPAB,EPAB,DWPI	lm609	4	<u>L5</u>
USPT	alphavbeta3 or alphaV adj beta3	1	<u>L4</u>
USPT	lm609	33	<u>L3</u>
USPT	cheresh-david\$	3	<u>L2</u>
USPT	brooks-peter\$	34	L1



Search Results -


Term	Documents
RGD.USPT.	1085
RGDS.USPT.	225
ANGIOGENESIS.USPT.	2484
ANGIOGENESES.USPT.	- 1
(RGD SAME ANGIOGENESIS).USPT.	. 39



Search History

Today's Date: 4/2/2001

<u>DB Name</u>	<u>Query</u>	Hit Count	Set Name
USPT	rgd same (angiogenesis)	39	<u>L7</u>
JPAB,EPAB,DWPI	rgd same (angiogenesis)	6	<u>L6</u>
JPAB,EPAB,DWPI	lm609	4	<u>L5</u>
USPT	alphavbeta3 or alphaV adj beta3	1	<u>L4</u>
USPT	lm609	33	<u>L3</u>
USPT	cheresh-david\$	3	<u>L2</u>
USPT	brooks-peter\$	34	<u>L1</u>



L7: Entry 10 of 39

File: USPT

Jul 25, 2000

US-PAT-NO: 6093399

DOCUMENT-IDENTIFIER: US 6093399 A

TITLE: Methods and compositions for the specific coagulation of vasculature

DATE-ISSUED: July 25, 2000

 $\begin{array}{c} \text{US-CL-CURRENT:} \ \ \underline{424/182.1}; \ \ \underline{424/178.1}, \ \ \underline{424/179.1}, \ \ \underline{424/180.1}, \ \ \underline{530/387.3}, \\ \underline{530/387.3}, \ \ \underline{530/387.7}, \ \ \underline{530/387.9}, \ \ \underline{530/388.1}, \ \ \underline{530/388.22}, \ \ \underline{530/388.85}, \ \ \underline{530/391.7}, \\ \underline{530/391.9} \end{array}$

APPL-NO: 8/ 482369

DATE FILED: June 7, 1995

PARENT-CASE:

The present application is a continuation-in-part of U.S. patent application Ser. No. 08/273,567 (ABN), filed Jul. 11, 1994; which is a continuation-in-part of U.S. patent application Ser. No. 08/205,330, filed Mar. 2, 1994; which is a continuation-in-part of U.S. Ser. No. 07/846,349 (ABN), filed Mar. 5, 1992. The entire text and figures of the above-referenced disclosures are specifically incorporated herein by reference without disclaimer.

WEST

Generate Collection

L7: Entry 31 of 39

File: USPT

Jun 30, 1998

US-PAT-NO: 5773412

DOCUMENT-IDENTIFIER: US 5773412 A

TITLE: Use of peptides for altering .alpha..sub.V .beta..sub.3 -mediated

binding

DATE-ISSUED: June 30, 1998

US-CL-CURRENT: $\frac{514}{11}$; $\frac{514}{12}$, $\frac{514}{12}$, $\frac{514}{13}$, $\frac{514}{14}$, $\frac{514}{15}$, $\frac{514}{16}$, $\frac{514}{17}$,

530/317, 530/324, 530/325, 530/326, 530/327, 530/328, 530/329

DISCLAIMER DATE: 20150412

APPL-NO: 8/ 421696

DATE FILED: April 12, 1995

PARENT-CASE:

This application is a continuation-in-part of U.S. Ser. No. 08/303,052, filed Sep. 8, 1994, which is a continuation-in-part of U.S. Ser. No. 08/227,316, filed Apr. 13, 1994 now abandoned.

06277001 EMBASE No: 1995307430

Antiintegrin alphavbeta3 blocks human breast cancer growth and angiogenesis in human skin

Brooks P.C.; Stromblad S.; Klemke R.; Visscher D.; Sarkar F.H.; Cheresh D.A.

Dept. of Immunology/Vascular Biology; Scripps Research Institute, 10666 North Torrey Pines Road, San Diego, CA 82037 United States Journal of Clinical Investigation (J. CLIN. INVEST.) (United States) 1995, 96/4 (1815-1822)

CODEN: JCINA ISSN: 0021-9738 DOCUMENT TYPE: Journal; Article

LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

Angiogenesis plays a fundamental role in human breast tumor progression. In fact, recent findings indicate that vascular density is a prognostic indicator of breast cancer disease status. Evidence is presented that the integrin alphavbeta3 is not only a marker of human breast tumor-associated blood vessels, but that it plays a significant role in human angiogenesis and breast tumor growth. To assess the role alphavbeta3-dependent angiogenesis in the progression of human breast cancer, we examined a SCID mouse/human chimeric model with transplanted full thickness human skin containing alphavbeta3-negative human breast tumor cells. This tumor induced a human angiogenic response as measured by vascular cell immunoreactivity with monoclonal antibodies LM609 and P2B1 directed to human alphavbeta3 and CD31, respectively. Intravenous administration of LM609 either prevented tumor growth or markedly reduced tumor cell proliferation within the microenvironment of the human skin. These LM609-treated tumors not only contained significantly fewer human blood vessels but also appeared considerably less invasive than tumors in control animals. These findings demonstrate that alphavbeta3 antagonists may provide an effective antiangiogenic approach for the